Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic

Полимерные системы доставки нуклеиновых кислот для терапии: на пути к клиническому применению
Wim E. Hennink, Raymond Michel Schiffelers, Chae‐Ok Yun, Annette I.S. van den Berg
2021-01-14

gene therapynon-viral carriersnucleic acid therapeuticspolymeric delivery systemspolyplexes
Gene therapy using nucleic acids has many clinical applications for the treatment of diseases with a genetic origin as well as for the development of innovative vaccine formulations. Since nucleic acids in their free form are rapidly degraded by nucleases present in extracellular matrices, have poor pharmacokinetics and hardly pass cellular membranes, carrier systems are required. Suitable carriers that protect the nucleic acid payload against enzymatic attack, prolong circulation time after systemic administration and assist in cellular binding and internalization are needed to develop nucleic acid based drug products. Viral vectors have been investigated and are also clinically used as delivery vehicles. However, some major drawbacks are associated with their use. Therefore there has been substantial attention on the use of non-viral carrier systems based on cationic lipids and polymers. This review focuses on the properties of polymer-based nucleic acid formulations, also referred as polyplexes. Different polymeric systems are summarized, and the cellular barriers polyplexes encounter and ways to tackle these are discussed. Finally attention is given to the clinical status of non-viral nucleic acid formulations.
1
Effective delivery systems must protect nucleic acid payloads, extend systemic circulation, and promote cellular binding and internalization.
2
Free nucleic acids require carrier systems because they are rapidly degraded by extracellular nucleases, exhibit poor pharmacokinetics, and inefficiently cross cellular membranes.
3
Polymeric nucleic acid formulations, or polyplexes, are reviewed with emphasis on their properties, cellular barriers, and strategies to overcome those barriers.
4
The clinical status of non-viral nucleic acid formulations is assessed, highlighting progress toward clinical application.
5
Viral vectors are clinically used but have important drawbacks, motivating development of non-viral carriers based on cationic lipids and polymers.

polymer-based nucleic acid formulations (polyplexes) for therapeutic delivery

their properties, cellular barriers, strategies to overcome these barriers, and clinical status

Publication Details
Publication Date
2021-01-14
Journal
Publisher
ISSN
Cited by
217
Access Type
Author Information
Authors
Wim E. Hennink
Raymond Michel Schiffelers
Chae‐Ok Yun
Annette I.S. van den Berg
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%